|
AMZ2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.6658454050098E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.82099907270117E-11 |
| Normal-vs-Stage2 |
2.570000E-02 |
| Normal-vs-Stage3 |
3.35389493955063E-11 |
| Normal-vs-Stage4 |
1.72817316013152E-12 |
| Stage1-vs-Stage2 |
1.655990E-02 |
| Stage1-vs-Stage3 |
2.267200E-01 |
| Stage1-vs-Stage4 |
1.201820E-02 |
| Stage2-vs-Stage3 |
3.115500E-03 |
| Stage2-vs-Stage4 |
3.619000E-04 |
| Stage3-vs-Stage4 |
3.328000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.6645573808205E-12 |
| Normal-vs-AfricanAmerican |
2.780800E-03 |
| Normal-vs-Asian |
4.15589999969157E-07 |
| Caucasian-vs-AfricanAmerican |
2.156000E-01 |
| Caucasian-vs-Asian |
2.454200E-01 |
| AfricanAmerican-vs-Asian |
7.475000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.54194451546164E-12 |
| Normal-vs-Female |
1.11609610442542E-11 |
| Male-vs-Female |
3.763600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.20630189065696E-11 |
| Normal-vs-Age(41-60Yrs) |
3.36697336678071E-12 |
| Normal-vs-Age(61-80Yrs) |
2.42329999955437E-07 |
| Normal-vs-Age(81-100Yrs) |
1.7155000000546E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.351000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.207000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.887830E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.379200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.731400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.628220E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.817000E-04 |
| Classical-VS-Follicular |
1.236330E-03 |
| Classical-VS-Other |
3.665200E-01 |
| Classical-VS-Normal |
2.99404945280912E-12 |
| Tall-VS-Follicular |
3.39720000019916E-07 |
| Tall-VS-Other |
7.451600E-02 |
| Tall-VS-Normal |
1.63036251166204E-12 |
| Follicular-VS-Other |
7.181000E-01 |
| Follicular-VS-Normal |
2.944700E-03 |
| Other-VS-Normal |
3.118300E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.55889995251601E-09 |
| Normal-vs-N1 |
5.79591930005563E-12 |
| N0-vs-N1 |
1.164160E-02 |
|
|
